<DOC>
	<DOCNO>NCT00002560</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining colony-stimulating factor , sargramostim , monoclonal antibody may effective treatment advance neuroblastoma . PURPOSE : Phase II trial study effectiveness monoclonal antibody 3F8 plus sargramostim treating patient advance neuroblastoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Plus Sargramostin Treating Patients With Advanced Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Define antitumor effect monoclonal antibody 3F8/sargramostim ( 3F8/GM-CSF ) patient advanced neuroblastoma . - Assess biological effect 3F8/GM-CSF patient . OUTLINE : Patients receive monoclonal antibody 3F8 IV 1.5 hour day 0-4 7-11 sargramostim ( GM-CSF ) IV 2 hour day -5 11 . Treatment repeat every 4 week 4 course absence progressive disease , HAMA response , unacceptable toxicity . PROJECTED ACCRUAL : A total 11-40 patient accrue study 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Neuroblastoma diagnose INSS criterion , i.e. , either : Histologic proof disease OR Tumor clump bone marrow plus elevated catecholamine level Relapsed disease poor longterm prognosis indicate least one following : Nmyc amplification tumor cell Diploid chromosomal content tumor cell Distant skeletal metastasis Unresectable primary tumor cross midline Bone marrow great 10 % tumor cell Documentation measurable progressive disease biopsy proven stable disease least 4 week prior systemic therapy require No rapidly progressive disease Poor risk neuroblastoma ( without measurable disease ) eligible neuroblastoma protocol PATIENT CHARACTERISTICS : Age : 2 21 Performance status : Not specify Life expectancy : Greater 8 week Hematologic : Not specify Hepatic : No grade 3/4 toxicity LDH great 1.5 time upper limit normal Renal : Creatinine clearance least 60 mL/min No grade 3/4 toxicity Cardiovascular : No grade 3/4 toxicity Pulmonary : No grade 3/4 toxicity Other : No grade 3/4 neurologic , gastrointestinal , organ toxicity except grade 3 hearing deficit No active life threaten infection No human antimouse antibody ( HAMA ) great 1,000 ELISA units/mL No allergy mouse proteins No pain require opiate PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Standard chemotherapy disease resistant myeloablative therapy follow disease recurrence require Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>